Triamcinolone acetonide aqueous intranasal - Sanofi
Alternative Names: Nasacort; Nasacort AQ; Nasacort® Allergy 24HR Nasal Spray; Triamcinolone acetonide water-based intranasal - Sanofi; XRG 5029Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis
Most Recent Events
- 10 Jul 2017 Sanofi completes in the phase III NASANIF trial for Perennial allergic rhinitis (NCT03317015)
- 12 Jun 2015 Non-prescription aqueous intranasal triamcinolone acetonide licensed to PENDOPHARM for commercialisation in Canada
- 11 Oct 2013 The US FDA approves Nasacort® as over-the-counter (OTC) product for treatment of Seasonal allergic rhinitis and Perennial allergic rhinitis in USA